Why the study?
STAT3 is overactivated in solid tumours, and further evidence was needed under controlled experimental conditions to clarify how asymmetric post-translational modifications affect the nuclear translocation of STAT3 homodimers.
Asymmetrically modified STAT3 homodimers exhibit altered nuclear translocation dynamics in response to LIF, suggesting a novel regulatory mechanism and potential therapeutic target for cancer.
Asymmetric PTM mutations alter STAT3 localization in cytokine-stimulated null cells; leaves open relevance to solid-tumor oncogenesis.
STAT3 is a pleiotropic transcription factor overactivated in 70% of solid tumours. We have recently reported that inactivating mutations on residues susceptible to post-translational modifications (PTMs) in only one of the monomers (i.e. asymmetric) caused changes in the cellular distribution of STAT3 homodimers. Here, we used more controlled experimental conditions, i.e. without the interference of endogenous STAT3 (STAT3-/- HeLa cells) and in the presence of a defined cytokine stimulus (Leukemia Inhibitory Factor, LIF), to provide further evidence that asymmetric PTMs affect the nuclear translocation of STAT3 homodimers. Time-lapse microscopy for 20 min after LIF stimulation showed that S727 dephosphorylation (S727A) and K685 inactivation (K685R) slightly enhanced the nuclear translocation of STAT3 homodimers, while K49 inactivation (K49R) delayed STAT3 nuclear translocation. Our findings suggest that asymmetrically modified STAT3 homodimers could be a new level of STAT3 regulation and, therefore, a potential target for cancer therapy.
No takes yet. Share an insight, caveat, or question.
Diallo et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: